论文部分内容阅读
作者测定了32例原发性肝癌、24例转移性肝癌、36例肝硬化病人的血清α-L-岩藻糖苷酶(AFU),并以30名肝功正常的健康人作为对照。测定结果表明,原发性肝癌病人的血清AFU 活性(145.2±12nkat/L)与正常人(51.4±4.5,P<10~(-7))、转移性肝癌(58.9±6.4,P<10~(-5))和肝硬化(71.3±6,P<10~(-5))比较,均显著增高,而正常人、转移性肝癌和肝硬化三组之间AFU 则无显著差异.75%的原发性肝癌病人AFU 值超过110nkat/L,而所有的正常人、继发性肝癌(除一例外)和大多数(89%)肝
The authors measured serum alpha-L-fucosidase (AFU) in 32 cases of primary liver cancer, 24 cases of metastatic liver cancer, and 36 cases of liver cirrhosis, and 30 healthy people with normal liver function were used as controls. The results showed that the serum AFU activity in patients with primary liver cancer (145.2±12nkat/L) was comparable to normal (51.4±4.5, P<10~7) and metastatic liver cancer (58.9±6.4, P<10~ (5)) and cirrhosis (71.3±6, P<10~(-5)) were all significantly higher, but there was no significant difference in AFU between normal, metastatic liver cancer and cirrhosis. AFU values in primary liver cancer patients exceed 110 nkat/L, while all normal, secondary liver cancer (except one exception), and most (89%) liver